ADAR1 Capital Management has made a significant investment in Denali Therapeutics, acquiring 1,819,339 shares during the first quarter of 2026.

The transaction is valued at approximately $36.20 million, based on the unadjusted average closing price of the stock over the quarter, as reported by Detik Finance.

>>> Roger Altman Warns Oil Price Spikes Threaten Stock Market Resilience

SEC Filing Details

According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, the acquisition increased the total quarter-end valuation of the position by $35.07 million.

This adjustment accounts for both the newly purchased shares and ongoing market price fluctuations.

Following the transaction, the Denali Therapeutics position represents 2.12% of ADAR1 Capital Management's total reported equity assets.

Portfolio Distribution and Market Performance

The SEC filing also reveals other major equity holdings managed by ADAR1 Capital Management after the first quarter of 2026.

The leading positions include:

>>> Bernstein and UBS Raise Delta Air Lines Price Targets on Strong Outlook

  • NASDAQ: ABVX at $155.22 million (9.4% of AUM)
  • NASDAQ: PTGX at $104.78 million (6.4% of AUM)
  • NASDAQ: ROIV at $91.02 million (5.5% of AUM)
  • NASDAQ: IMVT valued at $66.55 million (4.0% of AUM)
  • NYSEMKT: SPY valued at $49.39 million (3.0% of AUM)

As of May 17, 2026, Denali Therapeutics shares traded at $18.62, reflecting a 31.5% increase over the preceding year.

This performance allowed the biotechnology firm to outperform the S&P 500 index by 6.29 percentage points.

Biotech Drug Development and Investor Implications

Denali Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.

Its pipeline targets conditions such as Parkinson's disease, Hunter syndrome, ALS, multiple sclerosis, Alzheimer's disease, and lupus.

>>> XRP Spot ETFs Attract $1.39 Billion Inflow Despite Price Stagnation

The company has multiple candidates in Phase I and Phase II clinical trials.

Denali's business model centers on drug discovery and pipeline expansion, generating revenue through research collaborations and licensing agreements with pharmaceutical partners.

The company recently achieved a critical milestone with FDA approval of its first commercial drug for a rare brain disease.

Its core technology includes a proprietary platform capable of crossing the blood-brain barrier, addressing a key challenge in neurological drug development.

For investors, this acquisition represents a calculated bet on Denali's scientific platform and commercial potential.

>>> Federal Court Approves Wells Fargo $100 Million Mortgage Settlement

Key Financial Metrics

Denali Therapeutics reported a market capitalization of $2.96 billion, with a net loss of $508.02 million and a share price of $18.62 as of the latest filing.

Other schedules to note

  • May 20, 2026 - 13:18
  • According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, this strategic acquisition raised the total quarter-end valuation of the position by $35.07 million. This valuation adjustment accounts f
  • Villere St Denis J & Co LLC Cuts Tidewater Position by $9.34 Million
  • As of May 17, 2026, individual shares of Denali Therapeutics traded at $18.62, representing a 31.5% increase over the preceding year. This market movement allowed the biotechnology firm to outperform the S&P 500 index by
  • $2.96 billion443
  • $-508.02 million$18.62